Skip to content

Study · Randomized controlled trial · n = 30 · 2025

4 results

Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.

Jensterle M, Kovac J, Vovk A, Ferjan S, Battelino S, Battelino T, Janez A

The Journal of clinical endocrinology and metabolism1 Dec 2025Cited by 5 (Europe PMC)

PMID40341357 (opens in a new tab)DOI10.1210/clinem/dgaf278 (opens in a new tab)PepBankPUB-40341357
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with obesity and PCOS, semaglutide 1.0 mg weekly improved the overall taste recognition score from 11.9 to 14.4 points, a treatment difference of 2.5 points versus placebo.

    In plain wordsIn women with obesity and PCOS, semaglutide improved taste recognition more than placebo over 16 weeks.

    Peptide
    Semaglutide
    Outcome
    IncreaseOverall taste recognition score
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.0 mg once weekly · 16 weeksAs given in this study (human).

    Measurements

    Taste recognition score
    11.9 points
    baseline
    Taste recognition score
    14.4 points
    semaglutide
    Estimated treatment difference
    2.5 points
    vs placebo

    Source sentences

    Summary
    Semaglutide improved overall taste recognition score from 11.9 ± 1.9 points to 14.4 ± 1.0 points, with an estimated treatment difference of 2.5 points (95% CI, 1.7-3.3).
    1 context sentence
    Summary · context
    In this 16-week, single-blinded, placebo-controlled study, 30 women with polycystic ovary syndrome (PCOS), aged 33.7 ± 6.1 years with a body mass index of 36.4 ± 4.4 kg/m2 were randomized to semaglutide 1.0 mg once weekly or placebo.
  2. 02HumanRandomized controlled trialMechanism

    In women with obesity and PCOS, tongue biopsies showed differential RNA expression of EYA, PRMT8, CRLF1 and CYP1B1, genes linked to taste signalling, neural plasticity and taste bud renewal.

    In plain wordsIn women with obesity and PCOS, semaglutide was followed by changes in tongue gene activity linked to taste.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedRNA expression in tongue (taste-related genes)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The genes EYA, PRMT8, CRLF1, and CYP1B1, which are associated with taste signaling transduction pathways, neural plasticity, and renewal of taste buds, showed differential RNA expression by a multi-tiered analytical pipeline.
    2 context sentences
    Summary · context
    altered RNA expression in the tongue
    Summary · context
    In this 16-week, single-blinded, placebo-controlled study, 30 women with polycystic ovary syndrome (PCOS), aged 33.7 ± 6.1 years with a body mass index of 36.4 ± 4.4 kg/m2 were randomized to semaglutide 1.0 mg once weekly or placebo.
  3. 03HumanRandomized controlled trialMechanism

    In women with obesity and PCOS, semaglutide decreased activation of the putamen in response to visual food cues versus placebo (P < .001).

    In plain wordsIn women with obesity and PCOS, semaglutide reduced brain activity in the putamen when viewing food images, compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePutamen activation in response to visual food cues
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.0 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide decreased activation of putamen in response to visual food cues
    2 context sentences
    Summary · context
    (semaglutide vs placebo, P < .001).
    Summary · context
    In this 16-week, single-blinded, placebo-controlled study, 30 women with polycystic ovary syndrome (PCOS), aged 33.7 ± 6.1 years with a body mass index of 36.4 ± 4.4 kg/m2 were randomized to semaglutide 1.0 mg once weekly or placebo.
  4. 04HumanRandomized controlled trialMechanism

    In women with obesity and PCOS, semaglutide increased activity in the angular gyrus in response to sweet solution after meal intake versus placebo (P < .001).

    In plain wordsIn women with obesity and PCOS, semaglutide raised brain activity in the angular gyrus when tasting sweet liquid, compared with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseAngular gyrus activity in response to sweet solution
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.0 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    increased activity in the angular gyrus of the parietal cortex in response to sweet solution after meal intake
    2 context sentences
    Summary · context
    (semaglutide vs placebo, P < .001).
    Summary · context
    In this 16-week, single-blinded, placebo-controlled study, 30 women with polycystic ovary syndrome (PCOS), aged 33.7 ± 6.1 years with a body mass index of 36.4 ± 4.4 kg/m2 were randomized to semaglutide 1.0 mg once weekly or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.